Thalidomide in Treating Patients With Relapsed or Progressive Systemic Mastocytosis

Completed Centre Hospitalier Universitaire, Amiens

Summary

RATIONALE: Thalidomide may stop the growth of systemic mastocytosis by blocking blood flow to the disease. PURPOSE: This phase II trial is studying how well thalidomide works in treating patients with relapsed or progressive systemic mastocytosis.

Timeline

Start: 2007-06
Primary completion: 2011-05
Completion: 2012-10

Publications

Results Gruson B, Lortholary O, Canioni D, Chandesris O, Lanternier F, Bruneau J, Grosbois B, Livideanu C, Larroche C, Durieu I, Barete S, Sevestre H, Diouf M, Chaby G, Marolleau JP, Dubreuil P, Hermine O, Damaj G. Thalidomide in systemic mastocytosis: results from an open-label, multicentre, phase II study. Br J Haematol. 2013 May;161(3):434-42. doi: 10.1111/bjh.12265. Epub 2013 Feb 22.

Drugs

Evaluation	Drug	Modality	Dose	Route
Subject	Thalidomide	Other / unclassified	—	Oral

Indications

No indication recorded.